Otros idiomas Aligos Therapeutics, Inc.

Acciones

ALGS

US01626L1052

Mercado cerrado - Nasdaq Otros sitios de cotización 21:53:21 03/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,8099 ^USD	-4,27 %		+3,57 %	+21,97 %

03/04	Aligos Therapeutics, Inc. anuncia la dosificación de los primeros sujetos en el estudio de fase 2a HERALD de ALG-055009 en sujetos con MASH	CI
27/03	Aligos Therapeutics presenta datos clínicos positivos en APASL 2024 de los estudios de fase 1 ALG-055009 y ALG-000184	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024	30/04
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024	30/04
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study	25/04
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study	25/04
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD	25/04
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD	25/04
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024	09/04
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	03/04
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	03/04
Aligos Therapeutics, Inc. Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	03/04
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies	27/03
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies	27/03
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	18/03
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	18/03
Aligos Therapeutics, Inc. Announces the Initiation of the Phase 2a HERald Study of ALG-055009 in MASH Subjects	18/03
Aligos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results	12/03
Aligos Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12/03
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024	05/03
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024	26/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Aligos Therapeutics, Inc.

Acciones

ALGS

US01626L1052

Otros idiomas

Filtros